Intermittent Subcutaneous Apomorphine Therapy for ‘Off’ Episodes in Parkinson’s DiseaseA 6-Month Open-Label Study

被引：0
|
作者：
Richard M. Trosch
Dee Silver
Peter B. Bottini
机构：
[1] The Parkinson’s Disease and Movement Disorders Center,
[2] Coastal Neurological Group,undefined
[3] Mylan Laboratories Inc.,undefined
来源：
CNS Drugs | 2008年 / 22卷
关键词：
Apomorphine; Evaluation Visit; Dopamine Receptor Agonist; Motor Complication; Subcutaneous Apomorphine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose: The outpatient follow-up phase of the apomorphine (APO) 303 study assessed the long-term efficacy and safety of intermittent subcutaneous apomorphine for ‘off’ episodes in patients with advanced Parkinson’s disease.
引用
收藏
页码：519 / 527
页数：8
相关论文
共 50 条
  • [21] Clinical effect of tolcapone on continuous subcutaneous apomorphine in Parkinson's disease (PD): An open label study six month follow up
    Modugno, M.
    Alfonso, R.
    Lena, F.
    Ruggieri, S.
    Berardelli, A.
    Brunetti, A.
    MOVEMENT DISORDERS, 2008, 23 (01) : S317 - S317
  • [22] A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders
    Findling, Robert L.
    Robb, Adelaide S.
    DelBello, Melissa P.
    Huss, Michael
    McNamara, Nora K.
    Sarkis, Elias H.
    Scheffer, Russell E.
    Poulsen, Lis H.
    Chen, Grace
    Lemming, Ole M.
    Auby, Philippe
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2018, 28 (01) : 47 - 54
  • [23] Duloxetine for patients with diabetic peripheral neuropathic pain: A 6-month open-label safety study
    Raskin, Joel
    Wang, Fujun
    Pritchett, Yili Lu
    Goldstein, David J.
    PAIN MEDICINE, 2006, 7 (05) : 373 - 385
  • [24] The effect of pneumatic trabeculoplasty on intraocular pressure: The results of a 6-month, open-label, multicenter study
    Fogagnolo, P.
    Rossetti, L.
    Marchini, G.
    Marraffa, M.
    Rolando, M.
    Ciancaglini, M.
    Calabria, G.
    Mastropasqua, L.
    Orzalesi, N.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2008, 18 (06) : 922 - 928
  • [25] Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial
    Wei, JCC
    Chan, TW
    Lin, HS
    Huang, F
    Chou, CT
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (12) : 2627 - 2631
  • [26] OROS methylphenidate in the treatment of adults with ADHD: A 6-month, open-label, follow-up study
    Marchant, Barrie K.
    Reimherr, Frederick W.
    Halls, Corinne
    Williams, Erika D.
    Strong, Robert E.
    ANNALS OF CLINICAL PSYCHIATRY, 2010, 22 (03) : 196 - 204
  • [27] Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
    Greg W. Mattingly
    Peter M. Haddad
    Michael Tocco
    Jane Xu
    Debra Phillips
    Andrei Pikalov
    Antony Loebel
    BMC Psychiatry, 20
  • [28] A 6-MONTH OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS
    Furie, R.
    Rovin, B. H.
    Houssiau, F.
    Contreras, G.
    Curtis, P.
    Madan, A.
    Jones-Leone, A.
    Okily, M.
    Roth, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 591 - 592
  • [29] Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
    Mattingly, Greg W.
    Haddad, Peter M.
    Tocco, Michael
    Xu, Jane
    Phillips, Debra
    Pikalov, Andrei
    Loebel, Antony
    BMC PSYCHIATRY, 2020, 20 (01)
  • [30] Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study
    Correll, Christoph
    Koblan, Kenneth
    Hopkins, Seth
    Kent, Justine
    Cheng, Hailong
    Goldman, Robert
    Loebel, Antony
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 494 - 495
12345